NIH Grant Awarded
NIH Grant for Stroke Treatment Research
LAMIFLO™ is a disruptive technology in current stroke protocol because it can be administered in the pre-hospital phase; will increase the number of patients qualifying for treatment by thrombolysis or intra-arterial thrombectomy; and can be used in patients who do not qualify for either treatment and could be used in patients, days to months after a stroke who are still at risk for a second stroke. In two rat models of AIS by embolic and monofilament occlusion of the middle cerebral artery (MCA), the study evaluates by quantitative voxel analysis in MRI imaging, Lamiflo™ effectiveness in extending the duration of the ischemic penumbra and delaying the expansion of the core in without increasing hemorrhagic transformation. Positive results will support a Phase II application that includes development of the active pharmaceutical ingredient (API), InLife and toxicology studies for an Investigational New Drug (IND) application for FDA approval to pave the way to safety clinical trials.
Lamiflo™ is a high molecular weight polymer that enhances blood and red blood cell (RBC) flow by altering the physical dynamics of flow, not pharmacologically, and capable of increasing flow independent of tissue viability or vascular sensitivity.
WHEN DR. EDWIN NEMOTO, CEO, SHEARIT, joined the University of New Mexico in 2009, he brought with him the concept of cerebral microvascular shunts (MVS). Along with Dr. Wolfgang Mueller and Dr. Denis Bragin, they demonstrated, for the first time, the existence of brain MVS with loss of cerebral blood flow (CBF) regulation at high intracranial pressure. Along with Dr. Marina Kameneva’s assistance from the University of Pittsburgh, Dr. Nemoto and Dr. Bragin confirmed the efficacy of the polymer Lamiflo™ in reducing the severity of injury after stroke and traumatic brain injury. UNM Rainforest Innovations, the technology-transfer and economic development organization for the University of New Mexico, worked with our team to protect these novel findings in the form of filing utilization patents for Lamiflo™ for both AIS and cancer.
SHEARIT, has made great strides over the years to develop these innovative technologies and with the backing of the NIH we’re excited to see what is next on our journey to transforming stroke treatment and improving patient outcomes. Dr. Nemoto is promoting the notion that all vascular diseases can be attributed to MVS and has shown in animals that Lamiflo™ is effective in animal models of diabetes and Alzheimer’s Disease with plans for evaluation in sepsis and cancer.